Intravascular ultrasound assessed incomplete stent apposition and stent fracture in stent thrombosis after bare metal versus drug-eluting stent treatment the Nordic Intravascular Ultrasound Study (NIVUS)

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 1010-1016

  Kosonen, Petteri ^a,b   Vikman, Saila ^a   Jensen, Lisette Okkels ^c   Lassen, Jens Flensted ^d   Harnek, Jan ^e   Olivecrona, Göran K ^e   Erglis, Andrejs ^f   Fossum, Eigil ^g   Niemelä, Matti ^h   Kervinen, Kari ^h   Ylitalo, Antti ⁱ   Pietilä, Mikko ^j   Aaroe, Jens ^d   Kellerth, Thomas ^k   Saunamäki, Kari ^l   Thayssen, Per ^c   Hellsten, Lars ^m   Thuesen, Leif ^d   Niemelä, Kari ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b Savonlinna Central Hospital   (Finland)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e LUND UNIVERSITY   (Sweden)

^f PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^g ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^h OULU UNIVERSITY HOSPITAL   (Finland)

ⁱ SATAKUNTA CENTRAL HOSPITAL   (Finland)

^j TURKU UNIVERSITY HOSPITAL   (Finland)

^k ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

^l Rigshospitalet   (Denmark)

^m GÄVLE HOSPITAL   (Sweden)

more..

Author keywords

Bare metal stents; Drug eluting stents; Intravascular ultrasound; Stent thrombosis

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ADULT; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; HUMAN; INCOMPLETE STENT APPOSITION; INTRAVASCULAR ULTRASOUND; INTRAVASCULAR ULTRASOUND SYSTEM; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTHESIS FAILURE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; UNSTABLE ANGINA PECTORIS;

BARE METAL STENTS; DRUG ELUTING STENTS; INTRAVASCULAR ULTRASOUND; STENT THROMBOSIS;

AGED; BALTIC STATES; DRUG-ELUTING STENTS; EQUIPMENT FAILURE; FEMALE; HUMANS; MALE; METALS; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; SCANDINAVIA; STENTS; THROMBOSIS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84885318016     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.10.033     Document Type: Article

References (57)

1. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004;364: 583-91.
2. Morice MC, Serruys PW, Barragan P, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 2007;50:1299-304.
3. Virmani R, Farb A, Guagliumi G, Kolodgie FD. Drug-eluting stents: caution and concerns for long-term outcome. Coron Artery Dis 2004;15:313-8.
4. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
5. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
6. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-61.
7. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007;115: 1440-55 [discussion 1455].
8. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370: 937-48.
9. Jensen LO, Maeng M, Kaltoft A, et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 2007;50:463-70.
10. Kukreja N, Onuma Y, Garcia-Garcia HM, et al. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. JACC Cardiovasc Interv 2009;2:534-41.
11. Park DW, Yun SC, Lee SW, et al. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. JACC Cardiovasc Interv 2008;1:494-503.
12. Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008;52:1134-40.
13. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-78.
14. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293: 2126-30.
15. Le Feuvre C, Helft G, Cohen S, et al. Characteristics and prognosis of patients with angiographic stent thrombosis: comparison between drug-eluting and bare-metal stents. Arch Cardiovasc Dis 2008;101:220-5.
16. Jensen LO, Tilsted HH, Thayssen P, et al. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. EuroIntervention 2010;5:898-905.
17. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47: 175-81.
18. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-5.
19. Mintz GS, Nissen SE, Anderson WD, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001;37:1478-92.
20. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
21. Takebayashi H, Kobayashi Y, Mintz GS, et al. Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation. Am J Cardiol 2005;95:498-502.
22. Fujii K, Carlier SG, Mintz GS, et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol 2005;45:995-8.
23. Maehara A, Mintz GS, Lansky AJ, et al. Volumetric intravascular ultrasound analysis of paclitaxel-eluting and bare metal stents in acute myocardial infarction: the harmonizing outcomes with revascularization and stents in acute myocardial infarction intravascular ultrasound substudy. Circulation 2009;120:1875-82.
24. Ako J, Morino Y, Honda Y, et al. Late incomplete stent apposition after sirolimuseluting stent implantation: a serial intravascular ultrasound analysis. J AmColl Cardiol 2005;46:1002-5.
25. de la Torre Hernandez JM. Late acquired incomplete stent apposition: incidence, mechanisms and clinical implications. EuroIntervention 2009;5(Suppl. D): D112-20.
26. Hassan AK, Bergheanu SC, Stijnen T, et al. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur Heart J 2010;31:1172-80.
27. Steinberg DH, Mintz GS, Mandinov L, et al. Long-term impact of routinely detected early and late incomplete stent apposition: an integrated intravascular ultrasound analysis of the TAXUS IV, V, and VI and TAXUS ATLAS workhorse, long lesion, and direct stent studies. JACC Cardiovasc Interv 2010;3:486-94.
28. Degertekin M, Serruys PW, Tanabe K, et al. Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis. Circulation 2003;108:2747-50.
29. Hong MK, Mintz GS, Lee CW, et al. Impact of late drug-eluting stent malapposition on 3-year clinical events. J Am Coll Cardiol 2007;50:1515-6.
30. Hoffmann R, Morice MC, Moses JW, et al. Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials. Heart 2008;94:322-8.
31. Siqueira DA, Abizaid AA, Costa Jde R, et al. Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes. Eur Heart J 2007;28:1304-9.
32. Tanabe K, Serruys PW, Degertekin M, et al. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial. Circulation 2005;111:900-5.
33. Weissman NJ, Ellis SG, Grube E, et al. Effect of the polymer-based, paclitaxeleluting TAXUS express stent on vascular tissue responses: a volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials. Eur Heart J 2007;28:1574-82.
34. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
35. Cook S, Eshtehardi P, Kalesan B, et al. Impact of incomplete stent apposition on long-term clinical outcome after drug-eluting stent implantation. Eur Heart J 2012.
36. Lee CW, Kang S, Park D, et al. Intravascular ultrasound findings in patients with very late stent thrombosis after either drug-eluting or bare-metal stent implantation. J Am Coll Cardiol 2010;55:1936-42.
37. Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007;115: 2426-34.
38. Alfonso F, Dutary J, Rodriguez V, Zakhem B. Intravascular ultrasound and drug-eluting stents. Where are we now? Minerva Cardioangiol 2010;58:61-78.
39. Alfonso F, Suárez A, Pérez-Vizcayno MJ, et al. Intravascular ultrasound findings during episodes of drug-eluting stent thrombosis. J Am Coll Cardiol 2007;50: 2095-7.
40. Lee MS, Jurewitz D, Aragon J, Forrester J, Makkar RR, Kar S. Stent fracture associated with drug-eluting stents: clinical characteristics and implications. Catheter Cardiovasc Interv 2007;69:387-94.
41. Alfonso F, Perez-Vizcayno MJ, Ruiz M, et al. Coronary aneurysms after drugeluting stent implantation: clinical, angiographic, and intravascular ultrasound findings. J Am Coll Cardiol 2009;53:2053-60.
42. Mintz GS, Shah VM, Weissman NJ. Regional remodeling as the cause of late stent malapposition. Circulation 2003;107:2660-3.
43. Cook S, Ladich E, Nakazawa G, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009;120:391-9.
44. Kim YS, Koo BK, Seo JB, et al. The incidence and predictors of postprocedural incomplete stent apposition after angiographically successful drug-eluting stent implantation. Catheter Cardiovasc Interv 2009;74:58-63.
45. Guo N, Maehara A, Mintz GS, et al. Incidence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction: an intravascular ultrasound substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Circulation 2010;122:1077-84.
46. van der Hoeven BL, Liem SS, Dijkstra J, et al. Stent malapposition after sirolimuseluting and bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: acute and 9-month intravascular ultrasound results of the MISSION! intervention study. JACC Cardiovasc Interv 2008;1:192-201.
47. Canan T, Lee MS. Drug-eluting stent fracture: incidence, contributing factors, and clinical implications. Catheter Cardiovasc Interv 2010;75:237-45.
48. Nakazawa G, Finn AV, Vorpahl M, et al. Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis. J Am Coll Cardiol 2009;54:1924-31.
49. Chhatriwalla AK, Cam A, Unzek S, et al. Drug-eluting stent fracture and acute coronary syndrome. Cardiovasc Revasc Med 2009;10:166-71.
50. Yamada KP, Koizumi T, Yamaguchi H, et al. Serial angiographic and intravascular ultrasound analysis of late stent strut fracture of sirolimus-eluting stents in native coronary arteries. Int J Cardiol 2008;130:255-9.
51. Doi H, Maehara A, Mintz GS, et al. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials. JACC Cardiovasc Interv 2009;2: 1269-75.
52. Uren NG, Schwarzacher SP, Metz JA, et al. Predictors and outcomes of stent thrombosis: an intravascular ultrasound registry. Eur Heart J 2002;23:124-32.
53. Cheneau E, Leborgne L, Mintz GS, et al. Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation 2003;108:43-7.
54. Armstrong EJ, Kwa1 AT, Yeo KK, et al. Angiographically confirmed stent thrombosis in contemporary practice: insights from intravascular ultrasound. Catheter Cardiovasc Interv 2012, http://dx.doi.org/10.1002/ccd.24460.
55. Doyle B, Rihal CS, O'Sullivan CJ, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 2007;116:2391-8.
56. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011;57:1314-22.
57. Yamaji K, Inoue K, Nakahashi T, et al. Bare metal stent thrombosis and in-stent neoatherosclerosis. Circ Cardiovasc Interv 2012;5:47-54.